The value of permixon in benign prostatic hypertrophy.
A double-blind trial comparing the effect of Permixon (160 mg bd) against placebo in the treatment of benign prostatic hypertrophy is described. In both groups a significant improvement in flow rate and subjective assessment of symptoms was seen. There was no significant difference between the results of treatment in either group.
H
H
Reece Smith
A
A
Memon
C J
CJ
Smart
K
K
Dewbury
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D028024:Serenoa; D001743:Urinary Bladder / Q000503:physiopathology; D014554:Urination
D000726:Androgen Antagonists; D010936:Plant Extracts; C040972:saw palmetto extract